Research & Education

IASLC Lung Cancer Repeated Series: Advances in Treatment of Lung Cancer - 2016 Update

June 28, 2016 at 9:00 PM EDT - Recording Available
 Lauren Averett Byers  

Mark A. Socinski, MD
Professor of Medicine and Cardiothoracic Surgery
Director, Lung Cancer Section,
Division of Hematology/Oncology
Clinical Associate Director, Lung SPORE
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Leader, UPCI Lung Cancer Program

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine 

Name of Reviewer(s): 


Laurie Gaspar, MD, PhD- Advisory Board/Honoraria: Astrazeneca.

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose


Name of Activity: 


Advances in Treatment of Lung Cancer - 2016 Update

Date of Activity:



Faculty/Speaker(s) Disclosures:

COI Resolution:

Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.


Speaker: Mark A. Socinski, MD - Speakers' Bureau,  Advisory Board, Supported/Contracted Research/Grant from BMS, Lilly, Pfizer, Genentech, Clovis, BIND, Celgene,

Moderator: Ramaswamy Govindan, MD – Speakers or Advisory Board , Honoraria and consulting with the following: BI, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, ARAID Pharmaceuticals, Astellas; Honoraruim with the following: Baxalta, Roche


Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:

This live session of IASLC Lung Cancer Grand Rounds features Dr. Mark Socinski.  Dr. Socinski will highlight recent data in lung cancer, presented during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The program will focus on scientific and clinical progress most likely to impact the current management of patients with lung cancer.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to Dr. Socinski via internet chat.

After attending this program, participants will:

  • Illustrate key developments in clinical research most likely to impact patient care.
  • Recognize evolving standards and treatment paradigms.
  • Analyze treatment options in the personal medicine paradigm.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to Dr. Socinski via internet chat. 

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.  



IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

Please complete the evaluation link provided to you after the activity. The Certificate of credit will be ready for you to print or save for your records.

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2016. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

Use the Time Zone Converter